Raed Bargout, MD
Cardiovascular Disease · Los Angeles, CANPI 1962498410
Payments from drug & device makers
Across 299 payments — averaging $201.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$51K
- Abbott$4K
- Novartis$1K
- Boston Scientific$1K
- Medtronic$557
- AstraZeneca$373
- plus $2K from 22 others
Across 5 payments — averaging $2180.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$11K
What the payments were for
- Speaking & faculty fees$48,50081%
- Travel & lodging$2160%
- Food & beverage$11,14219%
- Education$210%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 101 | $50,584 |
| Abbott | 48 | $4,198 |
| Novartis | 41 | $1,295 |
| Boston Scientific | 16 | $1,116 |
| Medtronic | 5 | $557 |
| AstraZeneca | 20 | $373 |
| Cvrx, Inc. | 2 | $329 |
| Cardiovascular Systems Inc. | 3 | $237 |
| Johnson & Johnson | 9 | $229 |
| Abiomed | 2 | $208 |
| Amgen | 8 | $180 |
| E.r. Squibb & Sons, L.L.C. | 9 | $174 |
| Boehringer Ingelheim | 6 | $167 |
| Actelion Pharmaceuticals US, Inc. | 4 | $136 |
| Bayer | 4 | $128 |
| Pfizer | 4 | $82 |
| Lilly USA, LLC | 2 | $59 |
| Amarin Pharma, Inc. | 2 | $50 |
| Shockwave Medical, Inc | 2 | $48 |
| Merck | 2 | $37 |
| Teleflex LLC | 1 | $36 |
| Kestra Medical Technology Services, Inc. | 1 | $34 |
| Bard Peripheral Vascular, Inc. | 2 | $32 |
| Esperion Therapeutics, Inc. | 1 | $23 |
| Novo Nordisk | 1 | $22 |
| Irhythm Technologies, Inc. | 1 | $19 |
| Kowa Pharmaceuticals America, Inc. | 1 | $13 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LifeVest$49,289
- Quadra Assura CRT Defibrillator$756
- Confirm Rx$484
- Barostim Neo System$329
- Allure Quadra RF CRT Pacemaker$314
- Micra$305
- MitraClip$299
- CardioMEMS HF System$272
- Fortify Assura$271
- Coronary Orbital Atherectomy System$216
- S ICD$214
- RESONATE$212
- CARDIOMEMS$176
- MitraClip System$173
- S-ICD System Magnet$164
- GENERAL TACHY$163
- Fortify Assura, Ellipse ICD$161
- Quadra Allure MP RF CRT Pacemkr$149
- Impella$145
- Merlin Connectivity and Remote$143
How this compares
$60,379 in reported general payments places this provider in the 85th percentile of 2,184 cardiovascular disease providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 438 | $362,642 |
| JardianceEmpagliflozin | 360 | $259,593 |
| EntrestoSacubitril/Valsartan | 261 | $218,012 |
| OpsumitMacitentan | 13 | $165,753 |
| VascepaIcosapent Ethyl | 251 | $93,033 |
| BrilintaTicagrelor | 103 | $60,250 |
| XareltoRivaroxaban | 60 | $52,118 |
| MultaqDronedarone Hcl | 62 | $50,420 |
| Metformin Er GastricMetformin Hcl | 16 | $46,949 |
| Icosapent Ethyl | 182 | $34,157 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 14 | $23,850 |
| FarxigaDapagliflozin Propanediol | 31 | $17,182 |
| Repatha SureclickEvolocumab | 21 | $11,845 |
| Ranolazine ErRanolazine | 141 | $8,146 |
| LivaloPitavastatin Calcium | 13 | $7,976 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $82 | $362,642438 claims |
| Boehringer IngelheimJardiance, Combivent Respimat | $167 | $264,606371 claims |
| NovartisEntresto | $1,295 | $218,012261 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $136 | $165,75313 claims |
| AstraZenecaBrilinta, Farxiga | $373 | $77,433134 claims |
| Johnson & JohnsonXarelto | $229 | $52,11860 claims |
| Kowa Pharmaceuticals America, Inc.Livalo | $13 | $7,97613 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,184 cardiovascular disease providers in California.
Other cardiovascular disease in Los Angeles
- Kalyanam ShivkumarLos Angeles$2.9M
- Priscilla HsueLos Angeles$2.3M
- Cathleen Bairey-MerzLos Angeles$1.4M
- Somjot BrarLos Angeles$1.2M
- Freny ModyLos Angeles$960K
- Jamil AboulhosnLos Angeles$683K
- Parveen GargLos Angeles$653K
- Karol WatsonLos Angeles$553K
- Ted LoveHillsborough$102.8M
- Matthew BudoffTorrance$11.3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.